The recall includes 80 milligrams per 8-milliliter multi-dose vials and 160 milligrams per 16-milliliter multi-dose vials of docetaxel injection. The therapy is indicated for breast cancer, non-small cell lung cancer, castration-resistant prostate cancer, gastric adenocarcinoma, and head and neck squamous cell carcinoma.
If there’s a particulate matter in an injectable drug, patients face the risk of serious adverse events, the FDA said.
The particulates were detected in the product’s stopper, and to date, Sagent has not received any adverse event reports.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
